Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Uridine Prodrug Analogues: Uses in Cancer Diagnosis and Therapy Only written comments and/or license applications which are received by the National Institutes of Health on or before July 17, 2000 will be considered.
View Prospective Grant of Exclusive License: Second Generation Monoclonal Antibodies, and Humanized Carcinomas Only written comments and/or license applications which are received by the National Institutes of Health on or before June 23, 2000 will be considered.
View Prospective Grant of Exclusive License: NMR Glomerular Filtration Test and Kit Only written comments and/or applications for a license which are received by NIH on or before June 23, 2000 will be considered.
View Prospect Grant of Exclusive License: Therapeutic and Diagnostic Uses of Novel Thiolesters for HIV and Other Applications Only written comments and/or license applications which are received by the NIH Office of Technology Transfer on or before June 19, 2000 will be considered.
View National Cancer Institute (NCI) and the NIH Center for Information Technology (CIT): Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Software Enhancement for Expanding the Medical Uses of the TELESYNERGYTM Medical Consultation Workstation Interested parties should notify the Technology Development and Commercialization Branch of the NCI in writing of their interest in filing a formal proposal no later than thirty (30) days from the date of this announcement. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View Prospective Grant of Exclusive License: Development of Instruments for Diagnostic and Surgical Applications Based on Spectroscopic and Hyperspectral Imaging Techniques Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 3, 2000 will be considered.
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Screening, Development and Commercialization of Novel Inhibitors of GADD45 Polypeptide Activity for the Treatment of Cancer Interested parties should notify the Technology Development and Commercialization Branch of the NCI in writing of their interest in filing a formal proposal no later than May 26, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Research, Purification, and Further Development of a Factor(s) That Inhibits Human Immunodeficiency Virus (HIV) Replication Interested parties should notify this office in writing of their interest in filing a formal proposal no later than May 26, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View National Cancer Institute; Steroid Derivatives with Paclitaxel-Like Activity Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before June 20, 2000. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View National Cancer Institute; Targeted Screening for Inhibitors of Human Herpesvirus 8 DNA Polymerase Activity Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential, preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI within 30 days from date of this publication. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Use of Thymosin β4 for Wound Healing Applications Only written comments and/or license applications which are received by the National Institutes of Health on or before May 30, 2000 will be considered.
View Prospective Grant of Exclusive License: Uteroglobin in Treatment of IgA Mediated Autoimmune Disorders Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 18, 2000.
View Prospective Grant of Exclusive License: “Antibodies to Human Cripto Protein” and “Antibodies Specific for Human Cripto-Related Polypeptide CR-3” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 17, 2000 will be considered.
View Prospective Grant of Exclusive License: Autotaxin: Motility Stimulating Protein Useful in Cancer Diagnosis and Therapy Only written comments and/or license applications which are received by the National Institutes of Health on or before April 17, 2000 will be considered.
View National Cancer Institute: Development of Idiotype Tumor Vaccines for Treatment of B-Cell Lymphoma Organizations must submit a proposal summary preferably one page or less, to NCI within 90 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress and the Prophylactic and Therapeutic Treatment Radiation Damage to Normal Tissue Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 8, 2000, will be considered.
View Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress and in the Prophylactic and Therapeutic Treatment of Aging, Obesity and Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 8, 2000, will be considered.
View Prospective Grant of Exclusive License: Glycoprotein Hormone Superagonists Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 7, 2000, will be considered.
View Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Further Development and Commercialization of Methods Designed To Screen and Use Modulators of Nitric Oxide Synthase 2 (NOS2) Activity for the Diagnosis and Treatment of Cancer Interested parties should notify the Technology Development and Commercialization Branch of the NCI in writing of their interest in filing a formal proposal no later than ( February 11, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal.
View Secretary's Advisory Committee on Genetic Testing
View National Cancer Institute; Antitumor and Antimicrobial Lead Discovery and Development From Natural Products Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential, preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before January 31, 2000. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: ``Immunoconjugates Having High Binding Affinity'' Only written comments and/or applications for a license which are received by NIH on or before February 24, 2000 will be considered.
View Prospective Grant of Exclusive License: ``Diagnostic and Therapeutic Methods of Detecting and Treating Cancers of Reproductive Tissues'' Only written comments and/or applications for a license which are received by NIH on or before January 14, 2000.
View National Cancer Institute; Drug Research and Development of a Novel Vacuolar-Type (H+)-ATPase-Inhibitory Compound Class Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before December 10, 1999. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.